Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol
- PMID: 33030596
- DOI: 10.1007/s00520-020-05813-2
Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol
Abstract
Purpose: Neoadjuvant therapy (NT) is increasingly being offered to patients with pancreatic ductal adenocarcinoma (PDAC) prior to surgical resection. However, the experience and quality of life (QOL) of patients undergoing NT are poorly understood.
Methods: A systematic review of the Cinahl, Embase, Medline, Pubmed, Scopus, and Web of Science databases was conducted to evaluate the available literature pertaining to the experience and QOL of patient's undergoing NT for PDAC.
Results: Among 6041 articles screened, only six met criteria for full-text review including three prospective clinical trials of NT with QOL secondary endpoints. Overall, global QOL during or following NT did not significantly change from baseline. Pain scores seemed to improve during NT while the impact of NT on physical functioning varied across studies. No studies were identified evaluating other aspects of the patient experience.
Conclusion: Although NT appears to have a minor impact on the QOL of patients with PDAC, this systematic review identified significant evidence gaps in the literature. A protocol of a prospective observational cohort study utilizing a digital smartphone app that aims to evaluate the patient experience and longitudinal QOL of patients with PDAC undergoing NT is presented.
Keywords: Palliative care; Pancreatic ductal adenocarcinoma; Patient preferences; Patient-reported outcomes; Psychological impact; Supportive care.
References
-
- Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442 - DOI
-
- Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J (2017) Patterns, Timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 267:936–945. https://doi.org/10.1097/SLA.0000000000002234 - DOI
-
- Cloyd J, Shen C, Santry H et al (2020) Disparities in the use of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma. J Natl Compr Cancer Netw 18(5):1–8
-
- Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP, Talamonti MS (2007) Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer 110:1227–1234. https://doi.org/10.1002/cncr.22916 - DOI - PubMed
-
- Altman AM, Wirth K, Marmor S, Lou E, Chang K, Hui JYC, Tuttle TM, Jensen EH, Denbo JW (2019) Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival. Ann Surg Oncol 26:4108–4116. https://doi.org/10.1245/s10434-019-07602-6 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
